NCT06617442Completed
Esophageal Safety of High and Very High Power Short Duration Pulmonary Vein Isolation: a Randomized Comparison of the 50W and 90W Power Settings
Source: ClinicalTrials.gov · Last updated 27 Sept 2024
Brief summary (registry, in English)
Pulmonary vein isolation (PVI) is the most effective means of maintaining sinus rhythm in atrial fibrillation (AF), while a widely used approach to PVI is point-by-point radiofrequency (RF) catheter ablation. High power short duration (HPSD) and very high power short duration e.g., 90W and 4 sec) are increasingly popular technologies, featuring higher power and shorter application durations compared to previous methods. vHPSD offers similar efficacy to HPSD, while further reducing procedure times. Atrioesophageal fistula (AEF) is a rare but deadly complication of PVI, while endoscopically detected esophageal lesions are surrogate markers for the risk of AEF. Furthermore, thermal complications include vagal lesions leading to gastroparesis. While there is considerable data on the thermal safety of HPSD technology, most studies of vHPSD focus on efficacy and a direct comparison in terms of esophageal safety is lacking. In this randomized, single-center study, we aim to compare the thermal safety of vHPSD to HPSD. Furthermore, we aimed to determine the anatomical and biophysical factors that predict thermal injury. Patients undergoing their first PVI for AF are randomized to either HPSD or vHPSD power setting. The primary endpoint of the study is the composite of esophageal mucosal lesion and gastroparesis, as assessed at the post-procedural endoscopy within 15 days after the PVI.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 25 Sept 2024
- Start date
- 16 Feb 2022
- Primary completion date
- 4 Jul 2024
- Lead sponsor
- Semmelweis University
- Diseases
- Atrial fibrillation
- NCT number
- NCT06617442
What you commit to
- Study type: Interventional
- Participants enrolled: 150
- From 16 Feb 2022 to the primary completion date, 4 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Additional ablation performed outside PVI
- Contraindications to postoperative upper endoscopy
Who the study is looking for
- \- Patients with paroxysmal or persistent atrial fibrillation undergoing their first pulmonary vein isolation procedure
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Semmelweis University - Heart and Vascular Center Coordinator of this site? Confirm its status | Budapest | Hungary | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.